ABVC BioPharma, Inc.
ABVC
$2.77
$0.04011.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -91.08% | 2,289.94% | 1,819.67% |
| Total Other Revenue | -- | -- | 92.28% | -41.51% | -- |
| Total Revenue | -- | -- | -9.09% | 2,348.43% | 1,819.67% |
| Cost of Revenue | -- | -- | -100.00% | -98.99% | -99.73% |
| Gross Profit | -- | -- | 101.46% | 2,939.42% | 274.89% |
| SG&A Expenses | 141.45% | -76.03% | 0.50% | -84.94% | -41.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 3,891.67% | -256.48% | -- |
| Total Operating Expenses | 134.85% | -75.59% | -25.57% | -85.22% | -55.58% |
| Operating Income | -166.83% | 75.58% | 25.65% | 103.08% | 60.79% |
| Income Before Tax | -99.36% | 67.75% | 124.55% | 96.03% | 48.14% |
| Income Tax Expenses | 121.28% | -- | -100.00% | 140.00% | -235.74% |
| Earnings from Continuing Operations | -122.72% | 67.75% | 118.41% | 96.01% | 54.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -27.88% | 9.20% | -68.33% | -203.36% | 103.29% |
| Net Income | -139.52% | 70.29% | 159.82% | 94.38% | 58.37% |
| EBIT | -166.83% | 75.58% | 25.65% | 103.08% | 60.79% |
| EBITDA | -170.23% | 75.82% | 26.60% | 103.42% | 61.28% |
| EPS Basic | -56.01% | 80.66% | 130.31% | 98.17% | 87.84% |
| Normalized Basic EPS | -53.08% | 82.89% | -7.33% | 97.83% | 87.62% |
| EPS Diluted | -56.01% | 80.66% | 129.59% | 97.56% | 87.84% |
| Normalized Diluted EPS | -53.08% | 82.89% | -7.33% | 97.83% | 87.62% |
| Average Basic Shares Outstanding | 53.57% | 53.74% | 97.77% | 205.90% | 242.17% |
| Average Diluted Shares Outstanding | 53.57% | 53.74% | 97.77% | 205.90% | 242.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |